GLP-1 receptor agonists expand treatment options for diabetes, weight loss, and more, showing promise in heart failure, kidney disease, and neuroprotection.
Luke Evans, PharmD Candidate 2026
Advertisement
Articles by Luke Evans, PharmD Candidate 2026
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Reformulated Ranitidine After 5-Year Absence
2
Gluteus Maximus Muscle Shape Changes Tied to Aging, Frailty, and Type 2 Diabetes
3
Durvalumab Receives FDA Approval for Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
4
FDA Approves Sibeprenlimab for Patients with IgAN
5
